bioAffinity Technologies (BIAF) Return on Equity (2022 - 2026)

bioAffinity Technologies has disclosed Return on Equity across 5 years of filings, most recently posting 0.03% for Q1 2026.

• In Q1 2026, Return on Equity rose 2.0% year-over-year to 0.03%; the TTM figure through Mar 2026 stood at 0.03% (up 2.0% YoY), while the FY2025 annual figure was 0.03%, down 1.0% from the prior year.
• Return on Equity fell to 0.03% in Q1 2026, from 0.02% in the prior quarter.
• Over the last five years, Return on Equity for BIAF reached as high as 0.34% in Q2 2025 and fell as low as 0.05% in Q1 2025.
• The 5-year median for Return on Equity is 0.01% (2024), against an average of 0.01%.
• Annual changes were most pronounced in 2023 — Return on Equity fell 7 bps — and 2025, when it soared 36 bps.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then tumbled by 94 bps to 0.01% in 2023, then slumped by 136 bps to 0.03% in 2024, then jumped by 42 bps to 0.02% in 2025, then sank by 58 bps to 0.03% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.03%, 0.02%, and 0.04% for Q1 2026, Q4 2025, and Q3 2025 respectively.